Addex Therapeutics Financials
ADXN Stock | USD 7.89 0.11 1.38% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 1.39 | 1.4636 |
|
|
Investors should never underestimate Addex Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Addex Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Addex Therapeutics.
Net Income |
|
Addex | Select Account or Indicator |
Understanding current and past Addex Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Addex Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Addex Therapeutics' assets may result in an increase in income on the income statement.
Addex Therapeutics Stock Summary
Addex Therapeutics competes with Innate Pharma, Aptorum Group, Dyadic International, Soligenix, and Avenue Therapeutics. Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland. Addex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.Foreign Associate | Switzerland |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US00654J1079 |
CUSIP | 00654J107 00654J206 |
Location | Switzerland |
Business Address | Chemin des Mines, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.addextherapeutics.com |
Phone | 41 22 884 1555 |
Currency | USD - US Dollar |
Addex Therapeutics Key Financial Ratios
Return On Equity | -1.26 | ||||
Profit Margin | 5.00 % | ||||
Operating Margin | (7.80) % | ||||
Price To Sales | 10.10 X | ||||
Revenue | 1.61 M |
Addex Therapeutics Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 33.0M | 20.2M | 22.5M | 8.3M | 4.6M | 4.4M | |
Other Current Liab | 2.0M | 1.3M | 1.9M | 1.6M | 1.2M | 1.2M | |
Net Debt | (31.0M) | (18.1M) | (20.0M) | (6.6M) | (3.5M) | (3.7M) | |
Retained Earnings | (300.8M) | (313.7M) | (329.1M) | (349.9M) | (360.4M) | (378.4M) | |
Accounts Payable | 2.2M | 983.5K | 1.8M | 1.3M | 984.4K | 913.8K | |
Cash | 31.5M | 18.7M | 20.5M | 7.0M | 3.9M | 3.7M | |
Other Current Assets | 734.0K | 661.2K | 1.1M | 270.4K | 217.0K | 206.2K | |
Total Liab | 7.5M | 5.6M | 5.6M | 3.4M | 3.5M | 4.5M | |
Total Current Assets | 32.4M | 19.5M | 21.9M | 7.8M | 4.2M | 4.0M | |
Short Term Debt | 373.0K | 308.6K | 287.7K | 286.1K | 274.0K | 193.4K | |
Net Receivables | 118.0K | 68.4K | 324.4K | 598.3K | 151.3K | 271.7K | |
Other Liab | 639.4K | 1.6M | 1.7M | 1.3M | 1.5M | 813.2K | |
Net Tangible Assets | 25.5M | 14.6M | 16.9M | 4.9M | 5.6M | 5.4M | |
Other Assets | 68.9K | 59.1K | 57.9K | 54.4K | 48.9K | 66.0K | |
Net Invested Capital | 25.5M | 14.6M | 16.9M | 4.9M | 1.1M | 1.1M | |
Net Working Capital | 26.7M | 15.9M | 17.8M | 4.5M | 1.3M | 1.3M |
Addex Therapeutics Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 128.5K | 69.5K | 63.0K | 48.9K | 21.6K | 20.5K | |
Total Revenue | 2.8M | 3.6M | 2.9M | 1.4M | 1.6M | 2.7M | |
Gross Profit | 2.5M | (6.8M) | (9.9M) | (13.2M) | (5.3M) | (5.1M) | |
Operating Income | (14.8M) | (12.2M) | (15.5M) | (20.5M) | (10.3M) | (10.8M) | |
Ebit | (14.8M) | (12.8M) | (15.3M) | (20.6M) | (10.5M) | (11.1M) | |
Research Development | 12.5M | 10.4M | 12.8M | 14.7M | 2.7M | 2.6M | |
Ebitda | (14.2M) | (12.4M) | (14.9M) | (20.2M) | (10.2M) | (10.7M) | |
Income Before Tax | (14.8M) | (12.9M) | (15.4M) | (20.8M) | (10.6M) | (11.1M) | |
Net Income | (14.8M) | (12.9M) | (15.4M) | (20.8M) | (10.6M) | (11.1M) | |
Income Tax Expense | 128.5K | 207.8K | 116.4K | 123.9K | 21.6K | 20.5K | |
Cost Of Revenue | 230.1K | 10.4M | 12.8M | 14.6M | 6.9M | 5.6M | |
Interest Income | 176.5K | 35.3K | 5.3K | 29.3K | 64.0K | 65.8K | |
Net Interest Income | (91.6K) | (34.2K) | (57.7K) | (19.6K) | 42.4K | 44.5K |
Addex Therapeutics Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (10.1M) | (12.8M) | 1.8M | (13.5M) | (3.1M) | (2.9M) | |
Free Cash Flow | (9.5M) | (12.2M) | (14.7M) | (16.4M) | (8.0M) | (8.4M) | |
Depreciation | 333.8K | 378.8K | 347.6K | 323.1K | 306.0K | 290.7K | |
Other Non Cash Items | 523.9K | 972.6K | 32.9K | 204.1K | 249.6K | 140.4K | |
Capital Expenditures | 28.5K | 59.4K | 31.5K | 581.0 | 6.8K | 6.5K | |
Net Income | (14.8M) | (12.9M) | (15.4M) | (20.8M) | (10.6M) | (11.1M) | |
End Period Cash Flow | 31.5M | 18.7M | 20.5M | 7.0M | 3.9M | 3.7M | |
Investments | (43.3K) | (59.4K) | 1.2K | 3.0K | (6.8K) | (7.2K) | |
Change To Netincome | 2.3M | 2.1M | 1.1M | 3.9M | 4.5M | 4.7M |
Addex Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Addex Therapeutics's current stock value. Our valuation model uses many indicators to compare Addex Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Addex Therapeutics competition to find correlations between indicators driving Addex Therapeutics's intrinsic value. More Info.Addex Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Addex Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Addex Therapeutics' earnings, one of the primary drivers of an investment's value.Addex Therapeutics Systematic Risk
Addex Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Addex Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-two with a total number of output elements of nineteen. The Beta measures systematic risk based on how returns on Addex Therapeutics correlated with the market. If Beta is less than 0 Addex Therapeutics generally moves in the opposite direction as compared to the market. If Addex Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Addex Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Addex Therapeutics is generally in the same direction as the market. If Beta > 1 Addex Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Addex Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Addex Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Addex Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Addex Therapeutics December 12, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Addex Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Addex Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Addex Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Addex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Addex Therapeutics's daily price indicators and compare them against related drivers.
Information Ratio | (0.08) | |||
Maximum Drawdown | 29.35 | |||
Value At Risk | (7.40) | |||
Potential Upside | 9.74 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (21.75) | Revenue Per Share 1.2 | Quarterly Revenue Growth (0.82) | Return On Assets (0.62) | Return On Equity (1.26) |
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.